> Detailanzeige

Engel, Christoph; Fischer, Christine; Zachariae, Silke; Bucksch, Karolin; Rhiem, Kerstin; Giesecke, Jutta; Herold, Natalie; Wappenschmidt, Barbara; Hübbel, Verena; Maringa, Monika; Reichstein‐Gnielinski, Simone; Hahnen, Eric; Bartram, Claus R.; Dikow, Nicola; Schott, Sarah; Speiser, Dorothee; Horn, Denise; Fallenberg, Eva M.; Kiechle, Marion; Quante, Anne S.; Vesper, Anne‐Sophie; Fehm, Tanja; Mundhenke, Christoph; Arnold, Norbert; [...]

Breast cancer risk in BRCA1/2 mutation carriers and noncarriers under prospective intensified surveillance

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Breast cancer risk in BRCA1/2 mutation carriers and noncarriers under prospective intensified surveillance
  • Beteiligte: Engel, Christoph; Fischer, Christine; Zachariae, Silke; Bucksch, Karolin; Rhiem, Kerstin; Giesecke, Jutta; Herold, Natalie; Wappenschmidt, Barbara; Hübbel, Verena; Maringa, Monika; Reichstein‐Gnielinski, Simone; Hahnen, Eric; Bartram, Claus R.; Dikow, Nicola; Schott, Sarah; Speiser, Dorothee; Horn, Denise; Fallenberg, Eva M.; Kiechle, Marion; Quante, Anne S.; Vesper, Anne‐Sophie; Fehm, Tanja; Mundhenke, Christoph; Arnold, Norbert; [...]
  • Erschienen: Wiley, 2020
  • Erschienen in: International Journal of Cancer
  • Sprache: Englisch
  • DOI: 10.1002/ijc.32396
  • ISSN: 0020-7136; 1097-0215
  • Schlagwörter: Cancer Research ; Oncology
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:p>Comparably little is known about breast cancer (BC) risks in women from families tested negative for <jats:italic>BRCA1/2</jats:italic> mutations despite an indicative family history, as opposed to <jats:italic>BRCA1/2</jats:italic> mutation carriers. We determined the age‐dependent risks of first and contralateral breast cancer (FBC, CBC) both in noncarriers and carriers of <jats:italic>BRCA1/2</jats:italic> mutations, who participated in an intensified breast imaging surveillance program. The study was conducted between January 1, 2005, and September 30, 2017, at 12 university centers of the German Consortium for Hereditary Breast and Ovarian Cancer. Two cohorts were prospectively followed up for incident FBC (<jats:italic>n</jats:italic> = 4,380; 16,398 person‐years [PY], median baseline age: 39 years) and CBC (<jats:italic>n</jats:italic> = 2,993; 10,090 PY, median baseline age: 42 years). Cumulative FBC risk at age 60 was 61.8% (95% CI 52.8–70.9%) for <jats:italic>BRCA1</jats:italic> mutation carriers, 43.2% (95% CI 32.1–56.3%) for <jats:italic>BRCA2</jats:italic> mutation carriers and 15.7% (95% CI 11.9–20.4%) for noncarriers. FBC risks were significantly higher than in the general population, with incidence rate ratios of 23.9 (95% CI 18.9–29.8) for <jats:italic>BRCA1</jats:italic> mutation carriers, 13.5 (95% CI 9.2–19.1) for <jats:italic>BRCA2</jats:italic> mutation carriers and 4.9 (95% CI 3.8–6.3) for <jats:italic>BRCA1/2</jats:italic> noncarriers. Cumulative CBC risk 10 years after FBC was 25.1% (95% CI 19.6–31.9%) for <jats:italic>BRCA1</jats:italic> mutation carriers, 6.6% (95% CI 3.4–12.5%) for <jats:italic>BRCA2</jats:italic> mutation carriers and 3.6% (95% CI 2.2–5.7%) for noncarriers. CBC risk in noncarriers was similar to women with unilateral BC from the general population. Further studies are needed to confirm whether less intensified surveillance is justified in women from <jats:italic>BRCA1/2</jats:italic> negative families with elevated risk.</jats:p>
  • Zugangsstatus: Freier Zugang